Biosense Webster Develops First AF Ablation Catheter Following Atrionix Buy
This article was originally published in The Gray Sheet
Executive Summary
J&J/Cordis' $62.8 mil. cash acquisition of Atrionix rounds out Biosense Webster's electrophysiology product line with a catheter-based ablation approach to atrial fibrillation (AF).
You may also be interested in...
AF-Only Defibrillator Therapy May Be Five Years Away, Investigator Says
Implantable defibrillator therapy for the nearly 4 mil. atrial fibrillation patients not requiring ventricular defibrillation is at least three to five years away, Northwestern University electrophysiologist Alan Kadish, MD, indicated at the recent Lehman Brothers Healthcare Conference in Orlando, Florida.
P&G's $8M Benzene Settlement Preliminarily Approved By Ohio Federal Court
The Cincinnati, OH-based firm will pay $8m to recompense Unites States residents who purchased aerosol personal-care products potentially contaminated with benzene over a roughly six-year period.